FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
AOD 9604 is a synthetic peptide corresponding to residues 176-191 of human growth hormone, with a modified terminal structure used in laboratory investigation. For qualified laboratories, the relevant questions are not marketing claims. They are identity, peptide content, chromatographic purity, batch documentation, handling controls, and supplier traceability.
AOD 9604 is supplied exclusively for analytical, educational, and laboratory research. It is not a drug, food, dietary supplement, cosmetic ingredient, or product for human or veterinary use.
> Compliance Notice
>
> FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION. AOD 9604 must be handled only by qualified personnel in an appropriate research setting. It is not approved for diagnostic, therapeutic, prophylactic, or personal use. No material described here is intended for administration to humans or animals.
AOD 9604 Identity and Core Specifications
AOD 9604 is commonly described as a 16-amino-acid modified fragment related to the C-terminal region of human growth hormone. The sequence generally reported for the peptide backbone is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, represented in one-letter notation as YLRIVQCRSVEGSCGF.
The reported molecular weight of AOD 9604 is approximately 1,815.1 Da, although the exact observed mass may vary slightly according to salt form, counterion, analytical method, and reporting convention. Laboratories should use the batch-specific certificate of analysis rather than relying on a generic molecular-weight value for identity confirmation.
Research-grade procurement should prioritize more than a label claim. A useful batch record identifies the peptide, lot number, net content, analytical method, chromatographic purity result, and date of testing. High-performance liquid chromatography, commonly abbreviated HPLC, is typically used to assess purity profile, while mass spectrometry supports molecular identity verification.
For research workflows requiring defined material, a specification such as greater than 99% HPLC purity should be supported by documentation, not merely stated in product copy. A certificate of analysis and independent verification record provide materially stronger evidence than an unsupported purity percentage.
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
AOD 9604 Research Context
AOD 9604 has appeared in published and preclinical research as a discrete peptide fragment derived from growth-hormone sequence research. Researchers have examined the fragment in experimental systems intended to characterize peptide signaling, molecular interactions, metabolic-pathway observations, and tissue-model responses.
That research context requires careful interpretation. A short peptide fragment is not interchangeable with full-length growth hormone, and sequence origin does not establish equivalent receptor binding, pharmacology, stability, or biological activity. Results from isolated systems, cell cultures, or animal models cannot be assumed to translate beyond the specific model, concentration range, preparation method, and endpoints used in a given experiment.
The literature around AOD 9604 also illustrates a broader sourcing issue: a compound name alone does not establish what was tested. Experimental reproducibility depends on peptide identity, purity profile, storage history, solvent system, sample preparation, and whether the reported material contained impurities, truncated sequences, oxidation products, or other related substances.
When reviewing AOD 9604 research, laboratories should evaluate original publication records directly. Useful review points include the full peptide sequence, study model, analytical characterization of the test material, stated controls, exposure conditions, and statistical design. Product literature should never be used as a substitute for primary methods or independently verified analytical data.
Reported Mechanistic Questions in Laboratory Models
The mechanistic status of AOD 9604 remains a research question rather than a settled product attribute. Experimental work has explored whether this growth-hormone-derived fragment produces signals distinct from intact growth hormone and whether observed effects are associated with pathways involved in substrate handling, lipid-related cellular processes, or local tissue signaling in model systems.
For laboratory planning, the more useful framing is methodological: researchers may compare AOD 9604 with vehicle controls, scrambled-sequence controls, parent-protein comparators, or related fragments where the study design supports those comparisons. Endpoint selection should be appropriate to the model and should distinguish direct peptide-associated observations from nonspecific solvent, assay, or stress responses.
Analytical confirmation matters at every stage. Peptides containing cysteine residues can require particular attention during handling because oxidation, disulfide-related species, and repeated freeze-thaw exposure may alter the analytical profile. The sequence of AOD 9604 includes two cysteine residues, making post-reconstitution stability assessment especially relevant when a project requires extended storage or repeated sampling.
No mechanism should be inferred from a vendor specification sheet. Mechanistic findings require controlled experiments, validated assays, and reporting that allows another laboratory to assess or reproduce the observation.
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
AOD 9604 Quality Documentation
For a research peptide, the certificate of analysis is part of the material record. Before beginning work, verify that the COA corresponds to the exact lot in hand. The document should identify the material and lot number, state the testing method, report the HPLC purity result, and include mass-spectrometry data or an equivalent identity result where available.
Third-party analytical verification adds a meaningful control because it separates the manufacturing claim from independent test reporting. At minimum, laboratories should retain the supplier COA, any third-party result, purchase record, receipt date, storage history, and internal sample identifier with the experimental file.
The Peptide Source positions its research-grade peptide inventory around controlled production, manufacturer documentation, and additional third-party verification. For any AOD 9604 lot, researchers should review the available batch-specific documentation before using the material in an analytical workflow. A generic COA, an image without a batch match, or a report lacking method information should be treated as insufficient for traceability-sensitive work.
Purity is necessary but not exhaustive. A high HPLC percentage does not independently establish sequence fidelity, biological behavior, sterility, endotoxin status, or suitability for any specific assay. Those attributes require separate methods and specifications when relevant to a research protocol.
Storage and Laboratory Handling
Lyophilized peptides should be stored according to the batch label and accompanying documentation. Many peptide workflows use controlled frozen storage, protection from light where applicable, and moisture-limiting handling practices. The appropriate conditions depend on the specific formulation, container closure, intended study duration, and the supplier's batch instructions.
Following reconstitution for laboratory use, researchers should document solvent, concentration, preparation date, aliquot count, and storage condition. If repeated analysis is planned, a small pilot stability study can be more defensible than assuming that a preparation remains unchanged over time. HPLC or LC-MS comparison against the initial preparation can help identify material-profile changes under the selected storage conditions.
Avoid assigning a universal solubility value to AOD 9604. Solubility depends on pH, ionic strength, solvent composition, peptide concentration, temperature, and the presence of salts or excipients. A solvent system should be selected and qualified for the specific assay rather than copied from an unrelated protocol.
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
AOD 9604 FAQ
What is the AOD 9604 sequence?
The commonly reported peptide backbone sequence is YLRIVQCRSVEGSCGF. Confirm the sequence and any terminal modification against the batch-specific COA and product documentation.
What molecular weight should researchers expect?
AOD 9604 is commonly reported at approximately 1,815.1 Da. Confirm observed mass using the lot-specific analytical report because reported values can depend on salt form and method.
Does a 99% HPLC result confirm every quality attribute?
No. HPLC purity supports assessment of the chromatographic profile. Identity, peptide content, related substances, endotoxin, sterility, and stability require separate testing where those specifications matter.
Can a generic COA be used for lot verification?
No. A COA should match the lot number on the vial or packaging. Batch-specific documentation is necessary for a defensible material record.
What should be documented after reconstitution?
Record the solvent, concentration, date, storage condition, aliquot plan, and any subsequent analytical checks. These records support internal reproducibility.
Is AOD 9604 intended for personal use or administration?
No. AOD 9604 is for research use only and is not for human consumption. It is not intended for administration to humans or animals.
AOD 9604 research begins with verified material and disciplined records. Confirm the lot, retain the analytical documentation, qualify handling conditions for the assay, and keep every use within a legitimate laboratory research framework.
FOR RESEARCH USE ONLY - NOT FOR HUMAN CONSUMPTION.
Prepared by the Research Team at The Peptide Source.